Specialty Pharmacy

Expert discusses the patient-reported outcomes from the GRIFFIN trial at the final study analysis after all patients completed 1 year of follow-up post maintenance therapy.

Expert discusses updated cohort of patients with longer-term follow up treated in the phase 2 clinical trial of venetoclax added to cladribine plus low-dose araC alternating with azacytidine.

Expert discusses the updated data for a trial cohort after a median follow-up of 27 months.

Based on real-world outcomes, there is an unmet need for an effective therapy to be used among patients aged 75 years or older with relapsed/refractory diffuse large B-cell lymphoma.

Five crucial steps pharmacies can take to enhance patient engagement and lower operational costs.

Expert discusses the effect of baseline transfusion burden and luspatercept dose level on response to treatment in patients with LR-MDS from the MEDALIST study.

Expert discusses the results of a trial assessing immune reconstitution in adult patients who received Orca-T, consisting of hematopoietic stem/progenitor cells, regulatory T cells, and conventional T cells.

Expert discusses the safety and efficacy of polatuzumab vedotin combined with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) as second-line treatment in a multicenter phase 2 study.

Expert discusses analysis of phase 3 MEDALIST trial data aimed to assess the probability of greater overall survival and progression-free survival benefit from luspatercept vs placebo.

In recent decades, clinical trials have grown increasingly restrictive and exclusive, which has impacted the inclusivity and diversity of selected trial participants.

Mice receiving prophylactic recombinant factor FVIII and intravenous immunoglobulin for hemophilia A had reduced anti-FVIII antibodies versus mice who received FVIII only.

New system may more accurately identify IVIG resistance in North American patients with Kawasaki disease than the Kobayashi score.

Teplizumab is a humanized IgG1κ Fc-nonbinding anti-CD3 monoclonal antibody that blocks T cells, preventing them from attacking beta cells.

The allogeneic CAR-T cell therapy is in development for relapsed or refractory large B cell lymphoma and relapsed or refractory B cell non-Hodgkin lymphoma.

With the advent of disease-modifying therapies, the life span of patients with multiple sclerosis has increased dramatically.

Treatment with immune checkpoint inhibitors have the potential for immune-related adverse events, such as psoriasis.

Derazantinib is an investigational oral inhibitor of FGFR1, FGFR2, and FGFR3 in patients with locally advanced or metastatic intrahepatic cholangiocarcinoma.

Pharmacists can coordinate education programs for patients to normalize quality of life and minimize infusion-related pain.

The trial data demonstrated that pembrolizumab in combination with chemotherapy also had statistically significant and clinically meaningful improvements in PFS and ORR as well.

Pharmacists should engage patients, explore system fixes to prevent missed drug-drug interactions

The adeno-associated virus vector-based gene therapy is the first gene therapy to be approved by the FDA for hemophilia B.

IPX203 is a novel, oral formulation of carbidopa/levodopa extended-release capsules.

Stock shelves with boutique and unique products to anchor existing customer, attract new ones.

Pharmacists can coordinate educational programs for patients to normalize quality of life and minimize infusion-related pain.

Changes in DNA methylation may lead to accelerated aging in patients with cancer and HIV.

Complete due diligence before selecting a compounding pharmacy and establishing an outsourcing relationship.

Guselkumab (Tremfya) is a fully human selective IL-23 inhibitor therapy FDA-approved for the treatment of adults with active psoriatic arthritis and with moderate to severe plaque psoriasis.

Generic small molecule drugs take advantage of abbreviated approval pathways and have markedly lower development costs compared to their reference products.

When it comes to individualized treatment, “we can do better,” said John Edwards, vice president of Healthcare Solutions Consulting at SoftServe.

The goals of therapy for atopic dermatitis include reducing symptoms of pruritis and dermatitis with disease control and prevention of flares.